Skip to main content
LAB logo

LAB · Standard Biotools Inc.

Track LAB — free
$0.71 -0.04 (-4.99%) At close · Aug 14
Market Cap
$279.67M
Shares
392.58M

Standard Biotools Inc. Earnings Call Transcripts

Every quarterly earnings call for Standard Biotools Inc. (LAB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q2
2025-08-11
Standard Biotools Inc. Q2 FY2025 Earnings Call
Revenue
$21.76M
▼ 3.2% YoY
Diluted EPS
$-0.09
Gross margin
48.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Standard Biotools Inc. Q1 FY2025 Earnings Call
Revenue
$20.22M
▼ 55.6% YoY
Diluted EPS
$-0.07
Gross margin
54.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Standard Biotools Inc. Q4 FY2024 Earnings Call
Positive tone SomaLogic Integration & SomaScan Macro/Policy Backdrop Risk China Market & Geopolitics
Revenue
$890,000*
▼ 96.8% YoY
Gross margin
-202.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Standard Biotools Inc. Q3 FY2024 Earnings Call
Positive tone Consumables growth Geographic performance including China Revenue guidance reiteration and 2025 outlook
Revenue
$22.09M
▼ 12.9% YoY
Diluted EPS
$-0.07
Gross margin
54.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Standard Biotools Inc. Q2 FY2024 Earnings Call
Positive tone Illumina partnership and NovaSeq platform Leadership transition (CFO departure) SomaScan services and customer concentration
Revenue
$22.49M
▼ 18.7% YoY
Diluted EPS
$-0.12
Gross margin
46.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Standard Biotools Inc. Q1 FY2024 Earnings Call
Positive tone Illumina NGS partnership SomaScan assay and proteomics growth SomaLogic integration and synergies
Revenue
$45.54M
▲ 81.3% YoY
Diluted EPS
$-0.27
Gross margin
53.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Standard Biotools Inc. Q4 FY2023 Earnings Call
Confident tone SomaLogic merger and integration Product portfolio and technology platforms Revenue growth and 2024 guidance
Revenue
$28.19M*
▲ 4.3% YoY
Gross margin
47.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Standard Biotools Inc. Q3 FY2023 Earnings Call
Revenue
$25.37M
▼ 1.1% YoY
Diluted EPS
$-0.27
Gross margin
44.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Standard Biotools Inc. Q2 FY2023 Earnings Call
Revenue
$27.67M
▲ 47.3% YoY
Diluted EPS
$-0.22
Gross margin
49.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Standard Biotools Inc. Q1 FY2023 Earnings Call
Revenue
$25.12M
▼ 5.2% YoY
Diluted EPS
$-0.21
Gross margin
48.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Standard Biotools Inc. Q4 FY2022 Earnings Call
Revenue
$27.02M*
▼ 29.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Standard Biotools Inc. Q3 FY2022 Earnings Call
Revenue
$25.65M
▼ 10% YoY
Diluted EPS
$-0.37
Gross margin
36.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Standard Biotools Inc. Q2 FY2022 Earnings Call
Revenue
$18.78M
▼ 39.5% YoY
Diluted EPS
$-0.82
Gross margin
23.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Standard Biotools Inc. Q1 FY2022 Earnings Call
Revenue
$26.50M
▼ 19.2% YoY
Diluted EPS
$-0.99
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-18
Standard Biotools Inc. Q4 FY2021 Earnings Call
Revenue
$38.27M*
▼ 14.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Standard Biotools Inc. Q3 FY2021 Earnings Call
Revenue
$28.50M
▼ 28.5% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Standard Biotools Inc. Q2 FY2021 Earnings Call
Revenue
$31.02M
▲ 19% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Standard Biotools Inc. Q1 FY2021 Earnings Call
Revenue
$32.79M
▲ 18.7% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Standard Biotools Inc. Q4 FY2020 Earnings Call
Revenue
$44.61M
▲ 37.5% YoY
Gross margin
49.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Standard Biotools Inc. Q3 FY2020 Earnings Call
Revenue
$39.86M
▲ 50.4% YoY
Diluted EPS
$-0.08
Gross margin
52.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Standard Biotools Inc. Q2 FY2020 Earnings Call
Revenue
$26.06M
▼ 7.6% YoY
Diluted EPS
$-0.18
Gross margin
45.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Standard Biotools Inc. Q1 FY2020 Earnings Call
Revenue
$27.62M
▼ 8.3% YoY
Gross margin
47.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-14
Standard Biotools Inc. Q4 FY2019 Earnings Call
Revenue
$32.44M
▲ 0.4% YoY
Gross margin
54.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–23 of 23 earnings calls
Key facts CIK 1162194 CUSIP 34385P108 13F (30d) 141 filings 137 filers Visit website Investor relations